First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults-MedSci.cn

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults

Cicconi, P; Jones, C; Sarkar, E; Silva-Reyes, L; Klenerman, P; de Lara, C; Hutchings, C; Moris, P; Janssens, M; Fissette, LA; Picciolato, M; Leach, A; Gonzalez-Lopez, A; Dieussaert, I; Snape, MD

Cicconi, P (corresponding author), Churchill Hosp, Ctr Clin Vaccinol & Trop Med CCVTM, Old Rd, Oxford OX3 7LE, England.

Abstract

Background. Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mortality. This Phase I, randomized, observer-blind, pl......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults

科室

工具

服务